NCT05397431View on ClinicalTrials.gov

A Survey of Lanadelumab in Participants with Hereditary Angioedema

RecruitingOBSERVATIONAL
Enrollment

100

Participants

Timeline

Start Date

May 30, 2022

Primary Completion Date

January 31, 2026

Study Completion Date

January 31, 2026

Conditions
Hereditary Angioedema (HAE)
Interventions
DRUG

Lanadelumab

Lanadelumab 300 mg, subcutaneous injection every 2 weeks

Trial Locations (1)

Unknown

RECRUITING

Takeda selected site, Tokyo

Sponsors

Lead Sponsor

Takeda
All Listed Sponsors
lead

Takeda

INDUSTRY

NCT05397431 - A Survey of Lanadelumab in Participants with Hereditary Angioedema | Biotech Hunter | Biotech Hunter